ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alexion price cut opens up Strensiq to more patients
July 06, 2017NICE has recommended Strensiq in a wider group of patients with the ultra-rare disease paediatric-onset hypophosphatasia, after Alexion agreed a price cut. -
Alexion submits application to Japan’s MHLW to extend Soliris indication to treat gMG
March 27, 2017Alexion Pharmaceuticals has submitted an application to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalised myasthenia gravis (gMG). -
Alexion forecasts Soliris growth for 2017 in wake of probe into sales practices
February 17, 2017Alexion Pharmaceuticals on Thursday said that it anticipates Soliris sales in 2017 in the range of $3.03 billion to $3.1 billion, in line with analyst estimates. The therapy amassed about $2.8 billion in revenue for last year, compared to $2.6 billion in
Pharma Sources Insight January 2025
